Ardelyx, Inc. (ARDX)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Ardelyx, Inc. currently loses $1.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 18
in 88 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Ardelyx’s revenue rose ~16% year over year to about $127.7 million in the third fiscal quarter of 2026, based on preliminary results reported November 3, 2026, coming in line with consensus as revenue of $127.7 million versus a $128.0 million estimate (-0.3%). Sales remain centered on tenapanor across its gastrointestinal and cardiorenal focus, with revenue up from about $110.3 million a year ago. Profitability stayed high, with gross profit of roughly $123.1 million translating to a gross margin of ~96%. Cash generation was modest in the quarter, with operating cash flow of about $2.2 million. For the next period, consensus calls for EPS of $0.03 on revenue of $141.8 million.
About Ardelyx, Inc.
Ardelyx, Inc. is a NASDAQ-listed biotechnology company focused on gastrointestinal and cardiorenal conditions, with tenapanor as its marketed product and pipeline anchor. The company generated $407.3 million of revenue in FY2025. Ardelyx changed its name from Nteryx, Inc. and operates from Waltham, Massachusetts.
Today's Snapshot
ARDX closed 2.3% lower on heavier trading than usual.
Trading Volume
Above 10d avg 4.3M
6M
vs S&P 500 Today
Outperforming Market
+1.20%
Updated: November 20, 2026 at 21:07 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.07 - $4.76Sell
- RSI (14)43.07Neutral
- Stochastic %K (14, 3, 3)42.08Neutral
- MACD Level (12, 26)-0.05Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.